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Introduction/abstract 
Biliary Atresia and other cholestatic childhood diseases are rare conditions affecting the function 
and/or anatomy along the canalicular-bile duct continuum, characterised by onset of persistent 
cholestatic jaundice during the neonatal period. Biliary atresia (BA) is the most common among these, 
but still has an incidence of only 1 in 10–19,000 in Europe and North America. Other diseases such as 
the genetic conditions, Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis 
(PFIC), are less common. Choledochal malformations are amenable to surgical correction and require 
a high index of suspicion. The low incidence of such diseases hinder patient-based studies that include 
large cohorts, while the limited numbers of animal models of disease that recapitulate the spectrum of 
disease phenotypes hinders both basic research and the development of new treatments. Despite their 
individual rarity, collectively BA and other cholestatic childhood diseases are the commonest 
indications for liver transplantation during childhood. Here, we review the recent advances in basic 
research and clinical progress in these diseases, as well as the research needs. For the various diseases, 
we formulate current key questions and controversies and identify top priorities to guide future 
research. 
 
1. Diagnostic developments for neonatal cholestasis  
Key questions/controversies: 
• Which strategies can enhance earlier recognition of neonatal cholestasis, including BA? 
• What is the value of abdominal ultrasound, nuclear isotope excretion scan, liver biopsy and 
endoscopic retrograde cholangiopancreatography (ERCP) in the diagnostic work up?  
 
BA prognosis relates to timely surgical correction and early diagnosis (ideally before age 30 days) is 
therefore mandatory. Various diagnostic algorithms have been proposed [1-3].  A prompt diagnosis 
relies on the basic recognition that the infant has conjugated hyperbilirubinemia. Benign physiological 
or breast-milk associated unconjugated hyperbilirubinemia with normal color stools and urine is 
frequent, so the presence of acholic stools and pigmented urine should raise suspicion of liver disease 
in all jaundiced babies. Unfortunately, however, these symptoms can appear relatively late in biliary 
atresia and may go unrecognised. Thus, it has been recommended by the American Academy of 
Paediatrics that all infants with jaundice persisting beyond 2-3 weeks of age should have 
conjugated/direct bilirubin measured to identify those infants with cholestasis who require further 
evaluation in a referral unit [4], which should have the capacity to perform radiological imaging, liver 
biopsy interpretation and exclusion of genetic conditions mimicking BA within a few days days. 
Despite these recommendations, the average age at diagnosis and treatment of BA (~60 days)  has not 
changed over the past 20 years in the United States and many other countries [5, 6], and only 
decreased to some extent in the United Kingdom [7]. 
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New strategies to screen for neonatal cholestasis are clearly needed to enhance early diagnosis of BA.  
One such method is the provision of stool color cards to parents of newborns for identification of 
acholic stools. Routine screening for BA with stool color cards started in Japan in the 1990s [8], and 
was later introduced nationwide in Taiwan [9] and in Switzerland [10]. In Taiwan, five years after 
starting the stool color card screening, the rate of Kasai hepatoportoenterostomy (KPE) at  <60 days 
increased from 49% to 66%; the jaundice-free rate at 3 months after surgery from 35% to 61%, and 
the 5-year survival with native liver from 27% to 64% [9]. As reported by Matsui, a program 
involving 313,230 infants in Japan’s Tochigi Prefecture between 1994 and 2011 – with an 84% card 
return rate – demonstrated a sensitivity, specificity, positive predictive value, and negative predictive 
value for BA of 77%, 99.9%, 13%, and 99.9% respectively, with a native liver survival of BA children 
at 5, 10 and 15 years of 88%, 77% and 49% [11]. Recently, a large-scale prospective study 
demonstrated the practicality and cost effectiveness of the stool color card [12]. However, the success 
of a stool color card program may be more limited in countries without routine 30-day old well-child 
visits for review of the stool color card. Finally, the possibility of using direct/conjugated serum 
bilirubin measurements in newborns to screen for BA has recently been proposed [13] and is being 
pursued in different centers. 
 
The diagnostic role of endoscopic retrograde cholangiopancreatography (ERCP) remains 
controversial. In some centers with particular expertise, ERCP is used as a first-line diagnostic tool 
[14, 15], while in others it is limited to cases where the diagnosis remains doubtful after standard 
diagnostic tests (typically liver biopsy) [16]. Some centers rely heavily on ultrasound findings for the 
diagnosis of BA, including the “triangular cord” sign [17]. Most centers, however, consider ultrasound 
a complementary investigation, relying mostly on histological findings (liver biopsy) and exclusion of 
genetic disorders mimicking BA [18] in decision making for exploratory surgery. Nuclear isotope 
excretion scans are no longer frequently used: the absence of excretion into the intestines does not 
confirm BA. After the identification of cholestasis in an infant, diagnostic evaluation that would yield 
the diagnosis of BA should be completed within one week in order to expedite early surgery (before 
~35 days). Recognizing that genetic tests for syndromes of inherited cholestasis may take several 
weeks, they are not included in the typical diagnostic algorithm for BA. 
 
Top priorities for enhancing early diagnosis of neonatal cholestasis 
• We recommend a broader implementation of screening strategies, in particular the stool color 
card, with implementation that is tailored to country-specific infant care models. Educating 
parents of newborns is essential to the success of the stool color card program. To minimise 
diagnostic delay, patients with neonatal cholestasis should be evaluated in (or under guidance 
of) an experienced center that can complete the evaluation rapidly and, if indicated, can 
perform an intraoperative cholangiogram and KPE without delay.  
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2. Advancing the prognosis of biliary atresia 
Key questions/controversies: 
• To what extent has the prognosis of biliary atresia been characterised among different centers 
and countries and evolved over time?  
• What are the major causes and predictors of morbidity and mortality of patients with biliary 
atresia? 
• Is centralised care essential for improving prognosis?  
 
Paediatric registries have proven useful for detailing epidemiology of BA and for benchmarking both 
their short and long-term outcomes  [7, 19-23]. The UK registry was the basis for the first report of a 
significantly higher post-KPE jaundice-free survival rate in high (>5 cases/year)  vs. low surgical 
volume centers  resulting in centralization of KPE surgery to only 3 high volume centers [20, 24]. In 
contrast, France has a decentralised policy for the care of biliary atresia [6]. The National Institutes of 
Health sponsored Childhood Liver Disease Research Network (ChiLDReN) is a consortium of 16 
specialised centers in North America (www.childrennetwork.org), using similar clinical care protocols 
(without centralizing care) within prospective longitudinal study of 8 rare liver diseases, evaluating 
and tracking BA outcomes and their predictors [25]. Table 1 describes outcomes in several other 
disease registries, national or otherwise.   
  
The French registry reported a BA incidence of 1:19,400 live births [26], similar to other reports from 
Western Europe and Canada, and somewhat lower than the incidence in USA [19, 21, 22, 25, 27]. 
However, these rates are much lower than those reported from Asia (e.g. Japan, 1:9,640) [28] and in 
the smaller populations of French Polynesia (1:3,401) [29] and the Maoris of New Zealand (1:3,124) 
[30]. The reasons for this remain obscure.  
 
 
 
Top priorities for advancing the prognosis of biliary atresia 
• To study the relationships between clinical and therapeutic interventions and outcomes through 
expanding the reach and depth of data in databases. Expanded databases in BA will also facilitate 
collaborative studies to “enable better assessment of disease risk, understanding of disease 
mechanisms, and prediction of optimal therapy” – as proposed by the National Institute of Health 
of the USA [31]. The recently launched online registry “bard-online” (www.bard-online.com) 
might aid in the collection of multinational data, including from countries without registries.  
3. Treatment of biliary atresia after Kasai portoenterostomy 
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Key questions/controversies: 
• Which strategies following the KPE may delay or prevent the need for liver transplantation? 
• What are accepted prognostic parameters for long-term success of KPE?  
• What can be learned from variance in outcome of biliary atresia and KPE among different 
centers and countries?  
 
The most important advances for the long-term prognosis of BA have been the development of KPE 
[32] and of paediatric liver transplantation. The development of effective medical treatments following 
KPE to delay need for liver transplantation have been limited. Davenport et al. reported a randomised, 
double-blind placebo-controlled trial of oral prednisolone treatment versus placebo in BA patients 
post-KPE [33]. The steroid regime did not reduce the need for liver transplantation within 1 year, but 
sub-group analysis suggested beneficial effects on serum bilirubin in infants aged less than 70 days at 
KPE. In a follow-up open-labeled study in young BA patients (< 70 days at KPE), this observation 
was confirmed together with a statistically significant increase in the proportion to clear their jaundice, 
but without a statistical difference in either 4-year patient survival or native liver survival [34].  
 
In the largest randomised controlled double-blind clinical trial in BA thus far, Bezerra et al. studied the 
effects of a 13 week course of steroids, beginning with 4 weeks of high-dose intravenous or oral 
methylprednisolone versus placebo, on clearance of jaundice with native liver at 6 months after KPE 
[35]. The clearance of jaundice was not statistically different between the two groups, but a small 
clinical benefit could not be excluded. Survival with native liver at 2 years was virtually identical 
between the treatment and control groups. Earlier onset of serious adverse events occurred during 
treatment in the steroid group compared to the placebo group, raising concerns for high dose steroid 
therapy in the face of no demonstrable benefit.  
 
Some other drugs have been hypothesised to modify the prognosis of biliary atresia including 
antibiotics (administered in the immediate post-operative period after KPE or as prolonged 
prophylaxis against cholangitis) and choleretic agents, such as ursodeoxycholic acid. However, there 
are no published randomised controlled or pragmatic clinical trials post-KPE that are statistically 
powered to firmly support either antibiotic treatment or choleretic agents. Current use of these agents 
is therefore opinion- and center-based rather than evidence-based.  
 
The available trials indicate that age at surgery may influence the responsiveness to treatment. It has 
recently been proposed that the presence of cytomegalovirus IgM-positivity defines a phenotype of 
BA with inferior outcomes [36]. Thus, age at KPE and evidence of cytomegalovirus infection should 
be considered when establishing inclusion and exclusion criteria of future study designs. Another 
factor that may influence the (lack of) therapeutic response to steroids in biliary atresia is the stage of 
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disease, such as advanced fibrosis in patients older than 70 days of age at KPE. Recently, an 
unprecedented high success rate has been reported with respect to long-term native liver survival in 
Japan after portoenterostomy: 88%, 77% and 49% at 5, 10 and 15 years, respectively [11]. It is still 
unclear whether existing practices and techniques in Japan could be helpful in improving global 
outcomes of patients with biliary atresia. It cannot be excluded that differences in genetic background 
or environmental factors account for the improved prognosis. 
 
Top priorities for improving the treatment success of biliary atresia after Kasai 
portoenterostomy 
The high success rates recently reported in Japan suggest that the prognosis of BA can be further 
improved. Top priorities for improving the treatment success are: 
• Identification of predictors of the responsiveness to medical treatments after KPE, through 
analysis of clinical, laboratory, genetic and radiological characteristics. 
• Studies of environmental, medical, and surgical approaches that may be linked to the variance 
in outcomes in different centers and countries  
• Explore new therapeutic strategies (e.g., anti-fibrotic drugs or farnesoid X-receptor agonists) 
that presently are in development, particularly in adult cholestatic diseases, to assess their 
ability  to improve native liver survival  
 
4. Developments in understanding of the pathogenesis of biliary atresia 
Key questions/controversies: 
• What are the genetic susceptibility factors for BA? 
• Which viruses may trigger BA and does viral infection occur prenatally? 
• Does immune dysregulation or autoimmunity play a role in the progressive bile duct injury 
after KPE? 
• Do the intestinal microbiome and innate immunity play a role in BA pathogenesis and the 
rapid progression of fibrosis, even after successful KPE? 
• Is there evidence that a toxin or vascular insult causes human BA? 
 
There are several phenotypes of biliary atresia, each likely with its own etiology and mechanistic 
underpinning. Genetic expression studies combined with histologic examination of hepatobiliary 
tissues at diagnosis suggest that there may be inflammatory and fibrosing subtypes of BA, each with 
its own pattern of progression. There are subtypes of BA associated with congenital malformations 
(fetal or embryonic BA) suggesting abnormal bile duct morphogenesis in the etiology of BA. The 
Biliary Atresia Splenic Malformation syndrome (BASM; about 4-14% of cases) is associated with 
laterality defects which suggest a genetic or epigenetic etiology [37, 38]. Other subtypes include the 
presence of major congenital malformations but without laterality defects (<5% of cases) or (<5% of 
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cases) or those with laterality defects but without splenic malformation [39, 40]. Finally, a so called 
cystic biliary atresia has recently been described in up to 8% of BA [41], which includes the presence 
of a cyst within an otherwise obliterated biliary tree.    
 
The majority of BA infants do not have congenital malformations (“isolated BA”, formerly known as 
perinatal or acquired BA). Almost all BA infants in fact have elevated serum direct bilirubin within 
the first 5 days of life [42], calling into question if perinatal cases are not indeed all prenatal in onset. 
Several susceptibility genes have been described based on GWAS and targeting sequencing 
approaches [43-47]. There are at least two theories regarding pathogenesis of isolated BA, based on 
human observations and mouse models. A viral-induced, immune or autoimmune mediated 
inflammatory obstruction of the biliary tree is the most commonly accepted theory based on strong 
experimental evidence from the Rhesus Rotavirus (RRV) Balb/C newborn mouse model [48-50]. Both 
T-cell [51, 52] and B-cell-mediated autoimmunity [50, 53] have been implicated as well as 
dysfunction of regulatory T-cells [54, 55], activation of innate immunity and NK cells [56] and 
dendritic cells [57], activation of a pro-inflammatory gene footprint in liver tissue [58] and the loss of 
cholangiocyte primary cilia [59]. Recently, the contribution of interleukin-17 to the inflammation and 
destruction of the biliary system has been demonstrated, both in infants with BA and in the RRV 
newborn mouse model [60, 61].  
 
A more recent provocative toxin theory for BA pathogenesis is centered on a plant toxin (biliatresone), 
proposed to be responsible for both BA that occurs naturally in Australian livestock and for a BA-like 
lesion in zebrafish [62, 63]. Biliatresone appears to act by interfering with cholangiocyte polarity 
involving both Sox and Notch pathways. Ongoing investigations will need to determine the 
mechanisms of bile duct injury and obstruction by biliatresone and whether it is involved in human 
BA. 
 
Finally, a vascular hypothesis for biliary atresia is based on the findings of anatomic variants of 
hepatic artery and arterial hyperplasia in liver of some cases of human BA [64]. It is currently unclear 
however, whether vascular changes are causative, the result of injury or part of the remodeling process 
[65].  
In summary,  the available data point to roles of single-nucleotide polymorphisms (examples: CFC1 
and ADD3 genes) and extrinsic factors (examples: viruses and toxins) as susceptibility and/or 
triggering factors that target bile ducts. An initial injury may be accompanied by a dysregulated or 
immature immune response that produces the fibrosing and obstructing phenotype of biliary atresia 
(Figure). 
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Top priorities to understand the pathogenesis of biliary atresia 
Top priorities to increase the understanding of the pathogenesis are: 
• Identification of genetic variants that are more relevant to pathogenesis of syndromic forms of 
BA, and if found, characterise their functional significance. Assessment of possible influences 
of genetic variants on severity of disease and response to surgical treatment. 
• Systematic biological approach to identify if common immunological factors can be identified 
in the pathogenesis of BA and BA-related liver fibrosis and if they are amenable to therapeutic 
interventions. 
• Assessment of the role of specific toxins that target bile duct epithelia (e.g., biliatresone) in the 
pathogenesis of BA in humans. 
 
5. Choledochal Malformation 
Key questions/controversies: 
• Does prenatally discovered choledochal malformation (CM) require a different treatment 
strategy than postnatally diagnosed CM?  
• What is the right timing of surgery in patients with asymptomatic CM? 
• What is the life-long risk of bile duct malignancy in CM patients?  
 
The diagnosis and treatment of CM has been rather controversial, probably due to the very low 
incidence and the large variability in clinical and anatomical presentation. CM can be diagnosed pre- 
or postnatally. The optimal mode of diagnostic imaging and time of surgical resection remain unclear. 
Preliminary data from a recent Dutch survey highlight that: MRCP was routinely used in 71% and the 
more invasive ERCP in 29% of departments [66].  
The introduction of minimally invasive surgery (MIS) has certainly changed the approach to CM. 
Liem et al. confirmed the potential for excellent results in 400 Vietnamese children using a 
laparoscopic approach [67]. In a meta-analysis on 679 patients, Narayanan et al. reported no 
differences in the rates of bile leak, cholangitis, operative time, hospital stay and reoperation after 
laparoscopic hepaticoduodenostomy versus traditional hepaticojejunostomy [68]. However, the 
incidence of reflux/gastritis was much higher after hepaticoduodenostomy. At this moment there is a 
virtual absence of defined registries and of impartial assessment of the available diagnostic and 
therapeutic approaches to CM. Similarly, there is an absence of prospectively collected data on both 
the natural history of CM and its post-surgical course, which limits our ability to predict the long-term 
prognosis and cancer risk in individual patients.   
 
Top priorities to improve diagnosis and treatment of choledochal malformation 
• Development of multicenter/multi-country patient registries, such as “bard-online”, to allow 
(sub)classification of CM and assessment of treatment results and long-term course of disease. 
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Over time, the data can provide greater insights into variation in disease presentation and 
clinical course. 
• Defining the optimal surgical procedure, short- and long-term outcome, morbidities, optimal 
prevention and treatment of cholelithiasis, and the life-long risk of bile duct malignancy. 
 
6. Alagille Syndrome: diagnosis and treatment 
Key questions/controversies: 
• Are there effective medical treatments for intractable pruritus?  
• What is the spectrum of non-hepatic morbidities in affected patients? 
• Which patients benefit from liver transplantation and what is the outcome? 
 
Alagille syndrome (ALGS) is an autosomal dominant multisystem condition [69, 70] that is caused by 
mutations in JAG1 or NOTCH2 in the Notch signaling pathway. These mutations cause defective bile 
duct morphogenesis and angiogenesis, and abnormalities in skeletal, ocular, cardiovascular and kidney 
development [71]. 
 
ALGS is characterised by bile duct paucity and at least 3 out of 5 clinical features: cholestasis, cardiac 
defects, skeletal abnormalities, ocular abnormalities and characteristic facies [69]. The majority of 
patients with cholestasis have growth failure with fat malabsorption, metabolic bone disease, pruritus 
and hypercholesterolemia with xanthomas [72]. Management is based on intensive nutrition, fat 
soluble vitamin supplementation, choleretic agents and/or bile resins to reduce cholesterol.  
Management of pruritus is troublesome and may involve the addition of rifampicin or naltrexone. 
When medical treatment fails external partial biliary diversion may be required. Current clinical trials 
are investigating whether LUM001, which inhibits the apical sodium dependent bile acid transporter 
(ASBT) and prevents the reabsorption of bile acids in the terminal ileum, may improve quality of life, 
liver function, and reduce itching (Clinicaltrial.gov identifiers: NCT02047318, NCT01903460, 
NCT02057692, NCT02160782) [73, 74].  Cirrhosis and portal hypertension are rare early in childhood 
and 50% of children regain normal liver function without significant cholestasis by adolescence. 
However, only approximately 50% of ALGS patients presenting with neonatal cholestasis survive into 
adult life with their native liver. Management should include monitoring for the development of 
abdominal and intra-cranial vascular anomalies and for hepatocellular carcinoma, and 
multidisciplinary care of potential cardiac and renal failure [75-77].   
 
Indications for liver transplantation include liver failure and complications of portal hypertension, 
intractable pruritus or deforming xanthomata, repeated bone fractures due to intractable metabolic 
bone disease, growth impairment and poor quality of life. The assessment is complex because of 
multisystem involvement, particularly cardiac or renal disease, and the need to exclude vascular 
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anomalies. One and five year graft and patient survival are lower in ALGS than in BA with death <30 
days after transplant higher in ALGS due to graft failure, neurological, and cardiac complications [78]. 
Ocular disorders may include optic atrophy due to intracranial hypertension, retinal demyelination and 
chorioretinal atrophy [79]. Renal involvement occurs in 40% of JAG1 positive individuals. Renal 
dysplasia and renal tubular acidosis are common and renal insufficiency may require renal 
transplantation [71]. 
 
Top priorities to improve diagnosis and treatment of Alagille Syndrome  
• Clinical practice studies and patient registries to define the long-term natural history of disease 
(both hepatic and extra-hepatic manifestations) and the effects of interventions. Long-term 
monitoring of sequelae of ALGS is warranted (renal disease, cardiovascular disease, and in 
case of cirrhosis, development of hepatocellular carcinoma) using case-control analyses from 
adolescent and adult ALGS patients enrolled into registries. This will require the involvement 
of hepatologists treating adult patients. 
• Trials targeting either the pathogenesis of end-stage liver disease or of pruritus (including 
antifibrotic drugs and inhibitors of ASBT) are indicated. Given the low incidence of ALGS, 
collaboration across many centers will be mandatory in order to conduct properly powered 
clinical trials. 
• Develop a better understanding of the mechanisms by which partial biliary diversion may be 
beneficial, and prediction of which patients can benefit from these surgical interventions. 
 
 
7. Progressive Familial Intrahepatic Cholestasis (PFIC)  
Key questions/controversies: 
• What are the genetic and molecular underpinnings of PFIC or PFIC-like diseases? 
• What is the mechanism underlying the success of partial biliary diversion strategies and do 
they prevent the development of end-stage liver disease and hepatocellular carcinoma? 
• Do patients respond to strategies to medically reduce the bile acid pool size through inhibition 
of ASBT? 
• What are the mechanisms of increased risk of hepatocellular carcinoma in PFIC type 2?  
 
PFIC encompasses a group of autosomal recessive disorders of bile formation. Their pathogenesis can 
be divided into two groups based on the high or low level of serum gamma glutamyltransferase (GGT) 
[80-82]. In cholestasis, serum GGT is low when bile acids are not secreted into the bile and high when 
bile acids are secreted into the bile, but either concomitantly biliary phospholipid secretion is absent or 
bile outflow is obstructed. Low-GGT PFIC is associated with bile acid synthesis defects, and with 
mutations in ATP8B1 (PFIC type 1), ABCB11 (PFIC type 2), or TJP2 (TJP2 deficiency) [83-86]. The 
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mutant TJP2 protein is associated with defective cellular localization and disruption of tight-junction 
structure.  Up to 40% of phenotypic low-GGT PFIC cases do not have mutations in these genes. High-
GGT PFIC is associated with several diseases, among which are mutations in ABCB4 (PFIC type 3) 
[87]. 
 
Low-GGT PFIC is relentlessly progressive if not treated, although more rapid in PFIC type 2 
compared to PFIC type 1. The current first-line therapy is partial external bile diversion (PEBD) in 
patients with severe pruritus [88, 89]. This therapy appears to work by creating a relatively hydrophilic 
bile acid composition, thus improving bile formation [90]. Patients with no canalicular expression of 
functional BSEP (i.e. severe ABCB11 mutations) and patients who already have cirrhosis prior to 
PEBD can be expected to fail PEBD [91]. 
PEBD was first reported to be effective treatment for pruritus in PFIC in 1988 [88, 89] and has gained 
wide acceptance as the first-line therapy for low-GGT PFIC [88, 91-94] as well as in some cases of 
severe ALGS [91, 95]. It is effective in relieving pruritus in both conditions and improves growth, at 
the “cost” of an external stoma. Two variant approaches for biliary diversion recently have been 
reported, namely laparoscopic PEBD [96] and open button cholecystostomy [97]. Ileal exclusion has 
been used to treat pruritus in PFIC patients with some success [89, 98, 99], although in general it is 
considered less effective than PEBD. There has been a recent interest in internal surgical bile diversion 
from gallbladder to colon [100, 101], but the safety and efficacy of the procedure are as yet unproven.  
 
We feel that surgical approaches are still needed to interrupt the enterohepatic circulation with the goal 
to improve pruritus and growth, but there is no clinical trial demonstrating superiority of one surgical 
approach over the others. This notwithstanding, we have the general impression that ileal exclusion 
may not be as effective as PEBD. A common approach has been to perform PEBD, and the possible 
conversion to ileal bypass later in life, based on outcome and patient/family preference. If a biliary 
diversion approach fails, or if complications arise, (e.g., development of hepatocellular carcinoma in 
PFIC type 2 patients [102, 103]), liver transplantation is indicated.  
 
Non–surgical opportunities may be on the horizon to replace surgery as treatment for these diseases. 
For patients with specific mutations in ABCB11 (primarily miss-sense mutations), the basic transporter 
defect may be (partially) overcome by chaperones/small molecule strategies (e.g., 4-phenybutyrate and 
glycerol phenylbutyrate) that promote protein folding and enhance the functional expression of 
transport proteins in the liver [104]. Inhibition of intestinal bile acid absorption is being investigated as 
an alternative approach to treat these diseases. Miethke et al. recently inhibited ileal bile acid re-uptake 
using the competitive ASBT inhibitor SC-435 in Abcb4-/- mice, a model of PFIC type 3 [74]. SC-435 
treatment dramatically reduced plasma total bilirubin and ALT levels and improved liver histology 
and inflammatory gene expression compared to controls, suggesting that ASBT may be a promising 
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pharmacological target for “toxic” bile-induced cholangiopathies such as PFIC3. Counterintuitively, 
ASBT inhibition may also prove to be valuable for PFIC-1 and -2 patients, despite insufficient bile 
acid secretion across the canalicular membrane. PFIC-2 patients with at least some functional 
canalicular BSEP expression can be responsive to PEBD [91], and could therefore also be responsive 
by pharmacological interruption of the enterohepatic circulation. Clinical trials of ASBT inhibitors for 
treatment of PFIC (and ALGS) are underway (clinicaltrials.gov identifier: NCT02057718, 
NCT02160782, NCT02047318).  
 
Top priorities to improve diagnosis and treatment of PFIC 
A number of genes (ATP8B1, ABCB11, ABCB4, and TJP2) have been causally linked to the etiology 
of PFIC. The screening for mutations in these genes in the clinic should be incorporated into 
diagnostic algorithms for children with chronic cholestasis. Top priorities for the field moving forward 
are: 
• Establishing the relationships between PFIC genotype and therapeutic response (i.e. 
responsiveness to PEBD) is needed to better allow prognostication and personalise specific 
treatments in individual patients.  
• Determining whether newer surgical procedures to divert bile directly into the colon are 
effective and safe, and could replace external diversion strategies.  
• Identifying the mechanism underlying the increased risk of hepatocellular carcinoma in 
patients with PFIC-2. It has recently been shown that the genomic modifications in 
hepatocellular carcinoma of PFIC-2 patients can be distinguished from those arising in other 
cholestatic liver diseases [105], what could provide a target for elucidation of the mechanism.  
• Assessing the therapeutic value of new pharmacologic agents to interrupt the enterohepatic 
circulation of bile acids or improve intracellular trafficking of mutant protein.   
• Continue to identify new genetic causes of PFIC in patients negative for current genotypes 
 
8. Transition from paediatric to adult care for BA and other cholestatic childhood disease 
patients 
Key questions: 
• What are the most important medical risks for BA and BA related diseases patients reaching 
adulthood with their native livers and what is the optimal timing of listing for liver 
transplantation?  
• How can the transition from paediatric to adult care be facilitated through the acquisition of 
self-responsibility and self-management?  
 
There is an increasing proportion of patients with BA or another cholestatic childhood disease 
surviving into adulthood, requiring expertise in these disorders by adult-orientated physicians and 
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hepatologists. Up to 61% of BA patients with their native liver who reach adulthood develop severe 
hepatic complications, such as cholangitis, portal hypertension with variceal bleeding and, although 
infrequently, hepatocellular carcinoma [106]. Lind et al. reported that adult BA patients with native 
livers had a lower perceived general health and a higher score on the social domain section of the 
Health Status and Quality of Life questionnaire compared to the general population [107]. This is 
comparable to the ChiLDReN registry experience reporting that Health Related Quality of Life in BA 
children with native livers was poorer than in healthy children (although similar to BA patients who 
underwent liver transplantation), with poorer social functioning in the younger children [108].  
 
The indication and timing of liver transplantation in young adults with BA or another cholestatic 
childhood disease is challenging both from a medical and psychosocial point of view. Adult listing 
criteria might not be relevant to childhood liver diseases. Data on course of life in young adults 
transplanted in childhood show delay in reaching developmental milestones, but less risky behavior 
with regards to substance abuse and gambling compared to the general population [109]. Non-
adherence to treatment is a major concern in the post-transplant setting and the long-term graft and 
patient survival in patients transplanted between the ages of 12-17 years is poorer compared to the 
younger population. 
 
The present key issues of transition of care are partially related to cultural differences between 
paediatric and adult-oriented health care, as well as to unfamiliarity of the adult care-givers with the 
underlying diseases. Mutual awareness of patient specific health risks, typically involving disease-
related psychosocial development, is expected to result in patient-centered transition programs. 
Specific complication screening programs need to be developed since the diseases involved are 
usually accompanied by life-long increased risks. Currently unmet needs include proven strategies for 
adequately achieving self-responsibility and self-management by individuals who have had a severe 
medical condition that begins in the paediatric age [110]. King’s College Hospital (London, UK) is 
presently expanding the adult hepatology training program with a training course aimed at the care of 
young adult patients with a liver disease that originated in childhood.  
 
Top priorities to improve transition from paediatric to adult care for BA or other cholestatic 
childhood disease patients 
 
• The survival of BA or other cholestatic childhood disease patients into adulthood has created a 
rather novel patient group for adult-oriented health care professionals. Specific co-morbidities 
(e.g., cholangitis, portal hypertension, and short stature) and indications and timing of listing 
for transplantation in BA or another cholestatic childhood disease require close collaboration 
with paediatric hepatologists for development of clinical protocols for adult patients with BA 
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or another cholestatic childhood disease liver diseases in order to improve the outcome of 
these patients. 
 
 
SUMMARY AND PERSPECTIVES 
The prevalence of BA and other cholestatic childhood diseases is rare, which requires collaborative 
efforts to address the top priorities formulated for these these disorders (summarised in Table 2). 
Dissemination of current research advances in the context of BA has led to a unifying hypothesis 
(Figure 1). Isolation of a novel compound, biliatresone, causing natural biliary atresia in sheep (and in 
a zebrafish model) will open up a new research avenue. Areas of controversies that require new data 
include whether the centralization of BA surgery and care improves outcome. Determining the optimal 
screening strategies for BA and neonatal cholestasis is essential in order to ensure earlier diagnosis 
and better outcomes. The identification of new genetic causes of cholestatic childhood diseases 
continues, underlining the progress of insight as well as the value of detailed phenotypic and genetic 
analysis of the still unresolved causes of childhood cholestasis syndromes [111].  In related disorders, 
new therapies are emerging that are engineered to target the molecular cause or pathophysiology of 
certain types of PFIC and ALGS. These therapeutic advances will be a welcome addition to the rather 
limited therapeutic portfolio of treating the secondary metabolic and nutritional consequences and 
performing partial biliary diversion or liver transplantation. Until new therapies are shown to be 
effective and safe, ongoing multi-centered and multi-national collaboration to study these rare diseases 
is critical to continue the development and testing of novel therapies. With the current success of 
achieving adulthood in many patients, we are challenged to define the best strategies to transfer the 
care of these “grown children” from paediatric to adult-orientated liver clinics.  
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Figure 1 and Legend  
 
Potentially predisposing conditions
Single-nucleotide polymorphism
e.g. CFC1
Supposed extrinsic factors
Viruses
(CMV, reo, rota, 
HHV6, EBV, ..)
Bacteria Toxins
Dysregulated immune response
Others
Isolated biliary atresiaBA with associated anomaliesBASM
Intrauterine factors
e. g. maternal diabetes
Single-nucleotide polymorphism
e.g. GPC1, ADD3, ARF6
 
 
 
The two favored hypotheses for biliary atresia share the assumption of genetic predisposition. In 
patients with BASM, a single-nucleotide polymorphism in CFC1 has been described [43]. In patients 
with isolated BA, single nucleotide polymorphisms in other genes have been implied, such as GPC1, 
ADD3 and ARF6 [44-47]. In patients with a so-called acquired or isolated form of BA, the two-hit 
theory holds that extrinsic factors (e.g., an infectious agent or biliary toxin) might induce a 
dysregulated immune response, which may develop into a potentially self-perpetuating autoimmune 
process [38].  
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Legends 
Table 1 
Overview of national or multicenter registries on biliary atresia, based on published reports. 
 
Table 2  
Top priorities in research and clinical management of biliary atresia and cholestatic childhood disease. 
 
Table 1. Biliary Atresia Registries, national or otherwise 
Country, Period, and No. of centers No. of  No. of   Age at KPE Primary
 Survival            Survival  with Native Liver  Reference 
Follow up (median, range)    Patients KPE  days (in average) LTx
  overall   Total       Jaundice free*  
 
Canada, 1992-2002, 3 centers    230   207          64 10%  83% 
(1)
  39% (1)          n.a.  [23]  
Follow up  5.5 years (0.4 – 14.2 years) 
 
France, 1986-2009, 45 centers  1107  1044          59 4%  79% 
(2)
  40% (3)         38% (4)  [6]  
Follow up 9.5 years ( 0.3  - 24.6 years) 
 
Germany, 2001-2015, 29 centers 183  159          57 11%  83% 
(5)
  20% (5)        18% (5)  [112]  
Follow up 3.3 years (2.1-7.1)  
 
Japan, 1989-1999, 93 centers  1381  1181          n.a. 0.1%  75% 
(3) 
  60% (3)   57%** (4) [28]  
Follow up 5 resp. 10 years# 
 
Netherlands, 1987-2008, 6 centers 231  214          59 3%   73% 
(1)
  46% (1)  36% (1)  [21]  
Follow up 6.9 years (0.1 – 21.9 years) 
 
Switzerland, 1994-2004, 7 centers 48  43          68 10%  92% 
(3) 
  37% (3)   37% (3)   [113]  
Follow up 4 years#* 
 
UK&, 1999-2009, 3 centers  443  424         54  3%  89% 
(6)
  46% (1)  55% (7)  [7]  
Follow up 4 years 
 
USA/Biliary Atresia Research  104  104         61  n.a.##  87% 
(5)
   56% (5)  38% (7)  [25]  
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Consortium, 1997-2000; 9  
centers (not a national registry)  
Follow up 2 years# 
 
 
 
&
 United Kingdom (England and Wales); * jaundice free defined as bilirubin < 20 µmol/l; **  jaundice 
free defined as bilirubin < 34.2 µmol/l, # length of total follow up not available, ## patients not 
undergoing KPE had been excluded 
(1)
 4 years ; (2)  at last follow up ; (3)  5 years ; (4)  undefined period; (5) 2 years ;  (6) 10 years; (7) 6 months.  
KPE = Kasai hepatic portoenterostomy, LTx = liver transplantation, n.a. = not available 
  
20 
 
Table 2  
 
TOP PRIORITIES IN RESEARCH AND CLINICAL MANAGEMENT OF BILIARY ATRESIA 
AND CHOLESTATIC CHILDHOOD DISEASE 
Fundamental research 
- identification and functional characterization of genetic variants relevant for the pathogenesis 
of syndromic forms of BA 
- systematic biological approach to identify pathogenic factors in BA and in BA-related liver 
fibrosis 
- assessment of the role of specific toxins (e.g., biliatresone) in the pathogenesis of BA in 
humans  
- to identifying the molecular mechanism underlying the increased risk of hepatocellular 
carcinoma in patients with PFIC-2 
 
Clinical research and management 
- broad implementation of screening strategies, in particular the stool color card 
- evaluation of patients with neonatal cholestasis in an experienced center for rapid evaluation 
and, if indicated, Kasai hepatoportoenterostomy 
- to expand the databases of BA and other cholestatic childhood diseases to determine 
relationships between clinical and therapeutic interventions and outcomes 
- to analyse the variance in outcomes between different centers and countries  
- to assess the potential value of novel medical strategies (e.g. anti-fibrotic drugs, farnesoid X-
receptor agonists, ASBT inhibition, chaperones) for extending the native liver survival and/or 
decreasing pruritus 
- to establish patient registries for Alagille syndrome patients with monitoring of sequelae into 
adulthood 
- ability to prognosticate and personalise specific treatments in individual PFIC patients 
- to determine the safety and value of new surgical procedures based on internal biliary 
diversion colon  
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